Subscribe
clu
clu / iStockphoto.com
24 May 2018Americas

Fed Circuit sides with district court in UCB win against generics

Pharmaceutical company UCB has emerged victorious in a case against major generic drug companies after its patent win was affirmed on appeal.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
UCB challenges Teva generic drug application
3 July 2013   Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.
Americas
UCB sues MedImmune for patent infringement
15 December 2016   Biopharmaceutical company UCB Biopharma has filed a complaint against biotech developer MedImmune for alleged patent infringement.
Americas
Amerigen loses patent case against UCB at Federal Circuit
14 January 2019   US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
UCB challenges Teva generic drug application
3 July 2013   Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.
Americas
UCB sues MedImmune for patent infringement
15 December 2016   Biopharmaceutical company UCB Biopharma has filed a complaint against biotech developer MedImmune for alleged patent infringement.
Americas
Amerigen loses patent case against UCB at Federal Circuit
14 January 2019   US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.

More on this story

Americas
UCB challenges Teva generic drug application
3 July 2013   Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.
Americas
UCB sues MedImmune for patent infringement
15 December 2016   Biopharmaceutical company UCB Biopharma has filed a complaint against biotech developer MedImmune for alleged patent infringement.
Americas
Amerigen loses patent case against UCB at Federal Circuit
14 January 2019   US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent